Shin D, Jo J, Choi M, Kim K, Bae Y, Kim S. Oncogenic KRAS mutation confers chemoresistance by upregulating SIRT1 in non-small cell lung cancer. Exp Mol Med. 2023;55:2220-2237 pubmed publisher

Huynh M, Parsonage D, Forshaw T, Chirasani V, Hobbs G, Wu H, et al. Oncogenic KRAS G12C: Kinetic and Redox Characterization of Covalent Inhibition. J Biol Chem. 2022;:102186 pubmed publisher

Sad K, Parashar P, Tripathi P, Hungyo H, Sistla R, Soni R, et al. Prochlorperazine enhances radiosensitivity of non-small cell lung carcinoma by stabilizing GDP-bound mutant KRAS conformation. Free Radic Biol Med. 2021;177:299-312 pubmed publisher

Liu J, Sun M, Cho K, Gao X, Guo B. A CRISPR-Cas9 repressor for epigenetic silencing of KRAS. Pharmacol Res. 2021;164:105304 pubmed publisher

Inoue S, Hirota Y, Ueno T, Fukui Y, Yoshida E, Hayashi T, et al. Uterine adenomyosis is an oligoclonal disorder associated with KRAS mutations. Nat Commun. 2019;10:5785 pubmed publisher

Hrustanovic G, Olivas V, Pazarentzos E, Tulpule A, Asthana S, Blakely C, et al. RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. Nat Med. 2015;21:1038-47 pubmed publisher